BRIEF—Norgine agrees Korean deal for Plenvu

Netherlands-headquartered independent drugmaker Norgine has agreed a deal with Korea Pharma under which the Seoul-based manufacturer will commercialize Plenvu (1 liter PEG and ascorbate bowel preparation) in the Asian country.

Plenvu is a polyethylene glycol-based bowel preparation that is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel.

Jae-Don Park, chief executive and chairman of Korea Pharma, said: "Building on our strong presence and knowledge in the South Korea market, we look forward to making Plenvu available to healthcare professionals to help them to improve colonoscopy outcomes as well as patient experience and adherence to bowel cleansing instructions."